



State of New Jersey  
Department of Human Services  
Division of Medical Assistance & Health Services

# NEWSLETTER

Volume 33 No. 16

September 2023

**TO:** Hospitals, Physicians, Advanced Practice Nurses, Midwives, Independent Clinics, Providers of Pharmaceutical Services – **For Action**  
Managed Care Organizations – **For Information Only**

**SUBJECT:** **Compliance with the SUPPORT Act and requirements to utilize the New Jersey Prescription Monitoring Program (NJPMP) prior to prescribing and dispensing Controlled Dangerous Substances (CDS) for Medicaid/NJ Family Care members**

**EFFECTIVE:** Immediately

**PURPOSE:** To remind prescribers and providers of pharmaceutical services of their responsibilities to **utilize the NJPMP database** when prescribing and/or dispensing Controlled Dangerous Substances (CDS) for Medicaid/NJ FamilyCare beneficiaries.

**BACKGROUND:** On October 24, 2018, the **Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act** was enacted to combat the national opioid epidemic. Among its provisions, the SUPPORT Act mandates that states maintain a qualified prescription drug monitoring program. Additionally, most Medicaid/NJ FamilyCare providers are required to obtain information from the prescription drug monitoring program (PDMP) prior to prescribing controlled substances for Medicaid/NJ FamilyCare beneficiaries.

In line with this federal mandate, the New Jersey State Statute 45:1-45 et. seq. established the NJPMP. This program enables prescribers and pharmaceutical service providers to effectively monitor the utilization of CDS, gabapentin and Human Growth Hormone (HGH).

**ACTION:** **In order to ensure compliance with the SUPPORT Act**, Medicaid/NJ FamilyCare providers are being reminded of their obligation to comply with the laws and regulations governing the NJPMP. These regulations can be reviewed at the New Jersey Division of Consumer Affairs website:

<https://www.njconsumeraffairs.gov/pmp/Pages/regulations.aspx>

The NJPMP can be accessed at:

<https://newjersey.pmpaware.net>

**The Division of Medical Assistance and Health Services will be conducting routine compliance reviews.** These reviews are designated to validate and ensure the proper use of the NJPMP for Medicaid/NJ FamilyCare beneficiaries.

Should you have any questions or require further information, please contact the Gainwell Technologies Provider Services Unit at 1-800-776-6334.

**RETAIN THIS NEWSLETTER FOR FUTURE REFERENCE**